CARDIOVASCULAR HEALTH
is a tremendous story of scientifi c research,
according to Dr. Michael Lauer, di- rector, Division of Cardiovascular Sciences at the National Institutes of Health. “Heart disease is the quint- essential example of the scientifi c method really working to help public health,” he says. Through research, he explains, scientists fi nd ways to treat the disease and continue to look for new treatments. Here’s an example. Dr. Donald
Lloyd-Jones, chair, Department of Preventive Medicine, Feinberg School of Medicine, Northwestern University in Illinois, notes that between 2000 and 2010, the American Heart As- sociation (AHA) focused on reducing the death rate from heart attack and stroke. “Their goal was a 25-percent reduction in
that decade, and
they achieved more than 30,” he says. “We think it’s a combina- tion of bet- ter control of risk fac- tors and better
medical care.”
Lloyd-Jones was chair of the AHA team charged with establishing new goals for the decade from 2010 to 2020. “We wanted a new construct of cardiovascular health,” he recalls, “so we did a careful, science-based review of people with good cardio- vascular health and came up with our ‘simple seven.’ ” (See “My Life Check,” facing page.) “All seven are modifi able, all action-
able,” he says. “If you can make an im- provement in just one area, it can have a profound impact. For people with ideal levels of all of the seven, it acts like the fountain of youth. They live longer, and they live healthier, with a better quality of life at older ages. We spend less money on them. They also have less cancer, depression, and other chronic conditions like arthritis.”
New research “A major advance in aortic valve disease was the development of de- vices that can be inserted without open-heart surgery,” Lauer says. Until recently, the only eff ective treatment involved a major operation. “Now, we can remove a diseased valve and put in an FDA-approved prosthetic valve through a catheter,” he explains. “It’s
62 MILITARY OFFICER FEBRUARY 2016
a very impressive and complex proce- dure and is being done in reasonably high volume at dozens of specialized centers around the country.” Another promising area, he says, relates to “biological agents.” Today, most high cholesterol is treated with statins, which can have diffi cult- to-manage side eff ects. Scientists studied people with particularly low cholesterol levels who never develop cardiovascular disease and discov- ered they have a gene variation with PCSK9 inhibitors. (The PCSK9 gene is involved in cholesterol regulation.) “Work is being done to repro- duce this PCSK9 inhibitor,” explains Lauer, “and the FDA has just ap- proved two. These are not pills but [rather] injectables taken every two weeks, and they are very expensive. Where they fi t in the clinical tool set isn’t clear just yet, but there are some large-scale trials ongoing.” “Heart failure occurs when the heart muscle becomes diseased, dam- aged, or stiff , so it’s of great interest to learn how to regenerate or rejuvenate existing tissue,” Lauer says. “One par- ticular area of interest is stem cells, the idea being our heart started with stem cells [that] diff erentiated. If we
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56 |
Page 57 |
Page 58 |
Page 59 |
Page 60 |
Page 61 |
Page 62 |
Page 63 |
Page 64 |
Page 65 |
Page 66 |
Page 67 |
Page 68 |
Page 69 |
Page 70 |
Page 71 |
Page 72 |
Page 73 |
Page 74 |
Page 75 |
Page 76 |
Page 77 |
Page 78 |
Page 79 |
Page 80 |
Page 81 |
Page 82 |
Page 83 |
Page 84 |
Page 85 |
Page 86 |
Page 87 |
Page 88